A new clinical trial is underway at Vanderbilt University School of Medicine in Nashville, Tennessee, to explore an innovative use for a drug commonly prescribed to treat type 2 diabetes and obesity. The study, “Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-Related, Symptomatic Asthma (GATA-3),” may offer fresh hope for adults struggling with asthma linked to excess weight.
The randomized, placebo-controlled study involving 100 participants will investigate if semaglutide (Wegovy), a widely used glucagon-like peptide-1 (GLP-1) receptor agonist, can improve symptoms in adults with obesity-related asthma.
According to investigators, asthma and obesity are frequently intertwined conditions, with excess weight known to worsen respiratory symptoms and reduce the effectiveness of standard treatments, such as inhaled steroids. This study, they said, aims to determine whether semaglutide can address both metabolic and respiratory pathways simultaneously.
The trial focuses on adults aged 18 and older who have:
- A body mass index (BMI) of 30 or higher
- Persistent asthma symptoms despite existing treatment
- No diagnosis of type 2 diabetes
By targeting this specific group, researchers said they hope to better understand how obesity contributes to airway inflammation and whether metabolic therapies can intervene.
Trial participants will undergo:
- A four-week, pre-treatment monitoring period
- A 24-week treatment plan with either semaglutide or placebo
- A two-week, follow-up phase
Throughout the trial, researchers will closely track:
- Asthma symptoms and quality of life
- Lung function and airway responsiveness
- Biomarkers of inflammation in both the respiratory tract and adipose (fat) tissue
Semaglutide is already FDA-approved for managing diabetes and promoting weight loss, but scientists believe it may have broader effects, investigators noted. The central hypothesis driving this research, which is detailed in the trial description, is that the drug could directly reduce airway inflammation and improve asthma outcomes — not just through weight loss but via biological effects on the respiratory system itself.
If confirmed, this would represent a significant shift in how asthma — particularly obesity-related asthma — is treated. Specifically, researchers said the results could open the door to a new class of treatments for asthma patients who do not respond well to conventional therapies. Trial investigators also noted that current asthma medications primarily focus on relaxing airways or reducing inflammation, but they often fall short in patients whose condition is complicated by obesity.
If this proof-of-concept trial is successful, investigators said it could lead to larger, multisite trials in the future as well as:
- Expanded uses for GLP-1 receptor agonists
- New treatment guidelines for obesity-related asthma
- Improved quality of life for millions of patients worldwide
